|
US20050060764A1
(en)
*
|
2003-09-17 |
2005-03-17 |
Susan Gregory |
Mouse model for bone metabolism
|
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
|
US6919434B1
(en)
|
1995-02-20 |
2005-07-19 |
Sankyo Co., Ltd. |
Monoclonal antibodies that bind OCIF
|
|
US20050147611A1
(en)
*
|
1995-12-22 |
2005-07-07 |
Amgen Inc. |
Combination therapy for conditions leading to bone loss
|
|
US7632922B1
(en)
*
|
1995-12-22 |
2009-12-15 |
Amgen, Inc. |
Osteoprotegerin
|
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
|
US6479254B2
(en)
|
1996-03-22 |
2002-11-12 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II
|
|
US6495520B2
(en)
|
1996-03-22 |
2002-12-17 |
Human Genome Sciences, Inc. |
Apoptosis Inducing Molecule II and methods of use
|
|
PT1114864E
(pt)
*
|
1996-12-13 |
2008-10-08 |
Schering Corp |
Antigénios de superfície de células de mamífero, reagentes relacionados
|
|
CA2274803C
(en)
*
|
1996-12-23 |
2012-05-22 |
Immunex Corporation |
Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
|
|
DE69740107D1
(de)
|
1996-12-23 |
2011-03-10 |
Immunex Corp |
Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
|
|
ES2263204T5
(es)
|
1997-04-15 |
2013-10-14 |
Daiichi Sankyo Company, Limited |
Nueva proteína y proceso para producir la misma
|
|
AU2008200700C1
(en)
*
|
1997-04-15 |
2013-04-04 |
Daiichi Sankyo Co., Ltd |
Novel Protein and Process for Producing The Same
|
|
ES2284203T5
(es)
*
|
1997-04-16 |
2016-03-11 |
Amgen Inc. |
Proteínas de unión a osteoprotegerina y sus receptores
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
CA2229449A1
(en)
*
|
1997-04-25 |
1998-10-25 |
Takeda Chemical Industries, Ltd. |
Novel receptor protein and its use
|
|
AU7705098A
(en)
*
|
1997-05-29 |
1998-12-30 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like protein 8
|
|
JP4268684B2
(ja)
|
1997-09-24 |
2009-05-27 |
第一三共株式会社 |
骨代謝異常症の診断方法
|
|
WO1999029865A2
(en)
*
|
1997-12-12 |
1999-06-17 |
The Rockefeller University |
A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
|
|
US7019119B2
(en)
*
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
US7063960B2
(en)
*
|
1997-12-12 |
2006-06-20 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
AU762574B2
(en)
*
|
1998-05-14 |
2003-06-26 |
Immunex Corporation |
Method of inhibiting osteoclast activity
|
|
WO2001060397A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US20020106728A1
(en)
*
|
2000-06-20 |
2002-08-08 |
Genentech, Inc. |
NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
|
|
DK1114166T3
(da)
*
|
1998-09-15 |
2005-08-01 |
Pharmexa As |
Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
|
|
HUP0103578A3
(en)
*
|
1998-09-15 |
2005-11-28 |
Pharmexa As |
Method for down-regulating osteoprotegerin ligand activity
|
|
CA2365913C
(en)
|
1999-04-12 |
2015-03-03 |
Genentech, Inc. |
Tumor necrosis factor receptor homologs and nucleic acids encoding the same
|
|
US6492124B1
(en)
|
1999-06-11 |
2002-12-10 |
The Rockefeller University |
Trance activated signal transduction pathways in osteoclasts
|
|
US6872806B1
(en)
*
|
1999-06-25 |
2005-03-29 |
The Governors Of The University Of Alberta |
Polypeptide compositions formed using a coiled-coil template and methods of use
|
|
CN101633692A
(zh)
|
1999-06-28 |
2010-01-27 |
杰南技术公司 |
利用二价金属离子制备Apo-2配体的方法
|
|
US6673771B1
(en)
|
1999-07-28 |
2004-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of inhibiting osteoclast activity
|
|
AU778190B2
(en)
*
|
1999-07-28 |
2004-11-18 |
Trustees Of The University Of Pennsylvania, The |
Methods of inhibiting osteoclast activity
|
|
AUPQ314799A0
(en)
*
|
1999-09-29 |
1999-10-21 |
University Of Western Australia, The |
Bone cell factor
|
|
US6171860B1
(en)
*
|
1999-11-05 |
2001-01-09 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of rank expression
|
|
AU1920301A
(en)
*
|
1999-11-17 |
2001-05-30 |
Immunex Corporation |
Receptor activator of nf-kappa b
|
|
GB9930616D0
(en)
*
|
1999-12-24 |
2000-02-16 |
Mathilda & Terence Kennedy Ins |
Activation and inhibition of the immune system
|
|
SI1257648T2
(sl)
*
|
2000-02-23 |
2016-11-30 |
Amgen Inc. |
Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
|
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
|
HK1054316A1
(zh)
*
|
2000-05-26 |
2003-11-28 |
Smithkline Beecham Corporation |
用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
|
|
DE60136816D1
(de)
|
2000-07-27 |
2009-01-15 |
Genentech Inc |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
|
WO2002016551A2
(en)
*
|
2000-08-18 |
2002-02-28 |
University Of Massachusetts Medical Center |
Trance regulation of chondrocyte differentiation
|
|
AU2001288342A1
(en)
*
|
2000-08-21 |
2002-03-04 |
Smith Kline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
WO2002024896A2
(en)
*
|
2000-09-22 |
2002-03-28 |
Immunex Corporation |
Screening assays for agonists or antagonists of receptor activat or of nf-kb
|
|
US7128911B2
(en)
*
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
|
WO2002064782A2
(en)
*
|
2001-02-09 |
2002-08-22 |
Maxygen Holdings Ltd. |
Rank ligand-binding polypeptides
|
|
US20040132971A1
(en)
*
|
2001-02-09 |
2004-07-08 |
Haaning Jesper Mortensen |
Rank ligand-binding polypeptides
|
|
WO2002080955A1
(en)
*
|
2001-03-22 |
2002-10-17 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
US20030013651A1
(en)
*
|
2001-03-22 |
2003-01-16 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
IL157614A0
(en)
*
|
2001-03-23 |
2004-03-28 |
Genentech Inc |
Uses of opg ligand to modulate immune responses
|
|
WO2002092623A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Research Development Foundation |
INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
|
|
US20040167072A1
(en)
*
|
2001-05-11 |
2004-08-26 |
Aggarwal Bharat B. |
Inhibitors of receptor activator of NF-kappaB and uses thereof
|
|
CA2447518A1
(en)
*
|
2001-05-17 |
2002-11-21 |
Immunex Corporation |
Therapeutic use of rank antagonists
|
|
US20040213788A1
(en)
*
|
2001-05-18 |
2004-10-28 |
Sweet Raymond W. |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
MXPA03011270A
(es)
*
|
2001-06-06 |
2004-03-18 |
Immunex Corp |
Uso de antagonistas rank para tratar cancer.
|
|
WO2003002187A2
(en)
*
|
2001-06-26 |
2003-01-09 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
|
EP2295081B1
(en)
|
2001-06-26 |
2018-10-31 |
Amgen Inc. |
Antibodies to OPGL
|
|
EP1409544B1
(en)
|
2001-07-03 |
2009-06-17 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
US20030050223A1
(en)
*
|
2001-08-09 |
2003-03-13 |
Jonathan Lam |
Crystal forms and mutants of RANK ligand
|
|
EP1501866A4
(en)
|
2001-10-02 |
2006-02-08 |
Genentech Inc |
VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
|
|
CA2463478A1
(en)
*
|
2001-10-12 |
2003-08-14 |
Barnes-Jewish Hospital |
Methods for screening osteogenic compounds
|
|
US20030100068A1
(en)
*
|
2001-10-12 |
2003-05-29 |
Jonathan Lam |
RANKL mimics and uses thereof
|
|
US20030109444A1
(en)
*
|
2001-10-12 |
2003-06-12 |
Jonathan Lam |
Bone anti-resorptive compounds
|
|
IL161387A0
(en)
*
|
2001-10-15 |
2004-09-27 |
Barnes Jewish Hospital |
Rankl mimics and uses thereof
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
EP1450847B1
(en)
|
2001-11-13 |
2010-09-29 |
Genentech, Inc. |
APO2 ligand/ TRAIL formulations and uses thereof
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
AU2003217174A1
(en)
*
|
2002-01-04 |
2003-07-30 |
Xencor |
Novel variants of rankl protein
|
|
US20030166559A1
(en)
*
|
2002-01-04 |
2003-09-04 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
US20040170602A1
(en)
*
|
2002-01-04 |
2004-09-02 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
US7381792B2
(en)
*
|
2002-01-04 |
2008-06-03 |
Xencor, Inc. |
Variants of RANKL protein
|
|
AU2003210054A1
(en)
*
|
2002-03-21 |
2003-10-08 |
Komed Co., Ltd. |
Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
|
|
US7718776B2
(en)
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
|
EP2500032A1
(en)
|
2002-06-24 |
2012-09-19 |
Genentech, Inc. |
APO-2 ligand/trail variants and uses thereof
|
|
US20040138162A1
(en)
*
|
2002-08-30 |
2004-07-15 |
Roodman G. David |
Method of resisting osteoclast formation
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
JP2006521084A
(ja)
*
|
2002-12-10 |
2006-09-21 |
シェーリング−プラウ・リミテッド |
イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
|
|
CA2512085C
(en)
*
|
2003-01-10 |
2013-02-05 |
Protein Crystal Co., Ltd. |
Protein complex, process for producing the same and use thereof
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005028633A2
(en)
*
|
2003-09-17 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
Modulation of rankl expression
|
|
US7252833B2
(en)
*
|
2003-11-18 |
2007-08-07 |
Skeletal Kinetics, Llc |
Calcium phosphate cements comprising an osteoclastogenic agent
|
|
WO2005063170A2
(en)
*
|
2003-12-29 |
2005-07-14 |
Toudai Tlo, Ltd. |
Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
|
|
KR20060132006A
(ko)
|
2004-03-23 |
2006-12-20 |
비오겐 아이덱 엠에이 아이엔씨. |
수용체 커플링제 및 이의 치료적 용도
|
|
BRPI0513826A2
(pt)
|
2004-07-26 |
2010-06-22 |
Dow Global Technologies Inc |
processo para expressão de proteìna melhorada através de engenharia de cepa
|
|
WO2006015373A2
(en)
|
2004-08-04 |
2006-02-09 |
Amgen Inc |
Antibodies to dkk-1
|
|
MX2007001469A
(es)
|
2004-08-06 |
2007-03-26 |
Genentech Inc |
Ensayos y metodos que utilizan biomarcadores.
|
|
CN101061238B
(zh)
|
2004-08-06 |
2013-11-20 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
RU2411957C2
(ru)
*
|
2004-12-02 |
2011-02-20 |
Домантис Лимитед |
Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
CN101287990B
(zh)
|
2005-08-16 |
2012-07-04 |
健泰科生物技术公司 |
通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
|
|
ES2618543T3
(es)
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
|
WO2007095161A2
(en)
*
|
2006-02-14 |
2007-08-23 |
New York University |
Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
|
|
EP1854458A1
(en)
*
|
2006-05-08 |
2007-11-14 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Use of a compound with RANKL activity
|
|
JP5210156B2
(ja)
|
2006-05-12 |
2013-06-12 |
学校法人慶應義塾 |
炎症性疾患の検出並びに炎症性疾患の予防又は治療用組成物
|
|
WO2008044378A1
(en)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Reagent containing fused protein of soluble rankl with epitope tag
|
|
WO2008044797A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Animal modèle d'ostéopénie
|
|
WO2008044379A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Modèle animal de perte osseuse
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US20100260680A1
(en)
|
2007-06-05 |
2010-10-14 |
Oriental Yeast Co., Ltd. |
Novel bone mass increasing agent
|
|
US20100239590A1
(en)
*
|
2007-06-20 |
2010-09-23 |
Schering Corporation |
Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
|
|
PL2188313T3
(pl)
|
2007-08-21 |
2018-04-30 |
Amgen, Inc. |
Białka wiążące ludzki antygen c-fms
|
|
KR100911852B1
(ko)
|
2007-11-26 |
2009-08-11 |
고려대학교 산학협력단 |
유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
|
|
WO2009105934A1
(zh)
*
|
2008-02-27 |
2009-09-03 |
上海先导药业有限公司 |
抗人rankl单克隆抗体
|
|
TW201019959A
(en)
|
2008-08-19 |
2010-06-01 |
Regeneron Pharma |
Human antibodies to human RANKL
|
|
US8657662B2
(en)
|
2008-09-04 |
2014-02-25 |
Patent Investment & Licensing Company |
Gaming device having variable speed of play
|
|
US9435811B2
(en)
|
2008-09-30 |
2016-09-06 |
Oriental Yeast Co., Ltd |
Inducer of chondrocyte proliferation and differentiation
|
|
CN101712964B
(zh)
*
|
2008-10-08 |
2013-05-08 |
上海科新生物技术股份有限公司 |
抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
|
|
AU2009319864A1
(en)
|
2008-11-25 |
2011-07-14 |
Biogen Idec Ma Inc. |
Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
|
|
CN101514232B
(zh)
*
|
2009-03-25 |
2013-06-19 |
上海科新生物技术股份有限公司 |
一种RANKL-Fc融合蛋白及其制备方法和用途
|
|
US9079957B2
(en)
|
2009-04-16 |
2015-07-14 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
|
|
KR101153393B1
(ko)
*
|
2009-09-21 |
2012-06-07 |
고려대학교 산학협력단 |
점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
|
|
ES2993140T3
(en)
|
2010-04-02 |
2024-12-23 |
Amunix Pharmaceuticals Inc |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
TW201217527A
(en)
|
2010-07-09 |
2012-05-01 |
Biogen Idec Hemophilia Inc |
Processable single chain molecules and polypeptides made using same
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
EP2434285A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer diagnostics
|
|
EP3517630B1
(en)
|
2010-10-06 |
2022-01-19 |
Institució Catalana de Recerca i Estudis Avançats |
Method for the diagnosis, prognosis and treatment of breast cancer metastasis
|
|
WO2012133914A1
(ja)
|
2011-03-31 |
2012-10-04 |
オリエンタル酵母工業株式会社 |
Ranklアンタゴニストを含む癌免疫増強剤
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
FR2980711A1
(fr)
*
|
2011-10-03 |
2013-04-05 |
Centre Nat Rech Scient |
Modulation du systeme immunitaire et des cellules stromales via rank
|
|
WO2013067639A1
(en)
|
2011-11-07 |
2013-05-16 |
UNIVERSITé LAVAL |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
EP3467124A1
(en)
|
2012-06-06 |
2019-04-10 |
Fundació Institut de Recerca Biomèdica IRB (Barcelona) |
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
|
|
KR101872965B1
(ko)
|
2012-10-12 |
2018-06-29 |
인바이오모션 에스.엘. |
Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
WO2014144549A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Factor ix polypeptide formulations
|
|
WO2014184679A2
(en)
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
JP6577873B2
(ja)
|
2013-03-15 |
2019-09-18 |
フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） |
がんの転移の予後診断および処置のための方法
|
|
EP3030249B1
(en)
|
2013-08-07 |
2019-12-25 |
Rigshospitalet, Copenhagen University Hospital |
Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
|
|
WO2015030701A1
(en)
*
|
2013-08-24 |
2015-03-05 |
R-Pharm Overseas, Inc. |
Fully human antibodies against human rankl
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
TR201907389T4
(tr)
|
2013-10-09 |
2019-06-21 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
ES3055185T3
(en)
|
2014-03-28 |
2026-02-10 |
Univ Duke |
Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
|
CN104829725A
(zh)
*
|
2015-01-21 |
2015-08-12 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd133×cd3的构建及应用
|
|
KR20250152679A
(ko)
|
2015-04-29 |
2025-10-23 |
래디어스 파마슈티컬스, 인코포레이티드 |
암을 치료하는 방법
|
|
US10584174B2
(en)
|
2015-05-18 |
2020-03-10 |
Eli Lilly And Company |
Anti-Dkk-1-anti-RANKL bispecific antibody compounds
|
|
EP3299382B1
(en)
*
|
2015-05-20 |
2023-04-26 |
Osaka University |
Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
|
|
EP3400003B1
(en)
*
|
2016-01-05 |
2023-05-03 |
The Trustees of Columbia University in the City of New York |
Compositions for regulating activity of inhibitor of dna binding-2 (id2) protein
|
|
WO2017123642A1
(en)
*
|
2016-01-12 |
2017-07-20 |
The Trustees Of The University Of Pennsylvania |
Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
|
|
US11492386B2
(en)
|
2016-02-01 |
2022-11-08 |
Eli Lilly And Company |
Parathyroid hormone-anti-RANKL antibody fusion compounds
|
|
BR112018068103A2
(pt)
|
2016-03-08 |
2019-01-15 |
Janssen Biotech Inc |
anticorpos gitr, métodos e usos
|
|
AU2017271385B2
(en)
|
2016-05-25 |
2023-10-05 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-MAF status
|
|
CN110049773A
(zh)
|
2016-07-14 |
2019-07-23 |
供石公司 |
TGFβ抗体、方法和用途
|
|
CA3038850A1
(en)
|
2016-10-28 |
2018-05-03 |
Eli Lilly And Company |
Anti-rankl antibodies and uses thereof
|
|
JP7481115B2
(ja)
|
2017-01-05 |
2024-05-10 |
ラジウス ファーマシューティカルズ，インコーポレイテッド |
Ｒａｄ１９０１－２ｈｃｌの多形性形態
|
|
CA3056011A1
(en)
|
2017-03-14 |
2018-09-20 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
MX2020005182A
(es)
|
2017-11-22 |
2020-08-17 |
Inbiomotion Sl |
Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
MX2020013713A
(es)
|
2018-07-04 |
2021-03-02 |
Radius Pharmaceuticals Inc |
Formas polimorficas de rad1901-2hcl.
|
|
US11499928B2
(en)
*
|
2018-08-24 |
2022-11-15 |
University Of Wyoming |
Methods and systems for isochoric measurements using differential scanning calorimetry
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
JP7699542B2
(ja)
|
2018-11-20 |
2025-06-27 |
コーネル ユニバーシティー |
放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
|
|
EP3924328A1
(en)
|
2019-02-12 |
2021-12-22 |
Radius Pharmaceuticals, Inc. |
Processes and compounds
|
|
BR112022005583A2
(pt)
|
2019-09-26 |
2022-09-20 |
Amgen Inc |
Métodos para a produção de composições de anticorpos
|
|
EP4110371A1
(en)
|
2020-01-24 |
2023-01-04 |
Radius Health, Inc. |
Methods of stimulating bone growth with abalopartide and denosumab
|
|
CN111793135A
(zh)
*
|
2020-05-11 |
2020-10-20 |
廊坊天光生物技术有限公司 |
一种用于检测血清中rankl含量的抗体对及其用途
|
|
US20230273126A1
(en)
|
2020-06-04 |
2023-08-31 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
KR20230087539A
(ko)
|
2020-10-15 |
2023-06-16 |
암젠 인크 |
항체 생산 방법에서의 상대적인 비결합 글리칸
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
US20250076309A1
(en)
|
2021-10-05 |
2025-03-06 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
WO2023179791A1
(en)
*
|
2022-03-24 |
2023-09-28 |
Angitia Biomedicines Limited |
Treatment of musculoskeletal disorders
|
|
US20250249278A1
(en)
|
2022-04-14 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|